10 Best Short-Term Stocks To Buy Right Now

7. Puma Biotechnology, Inc. (NASDAQ:PBYI)

Last 52 weeks return: -36.40%

Last 1 month’s return: 16.08%

No. of hedge fund portfolios: 18

The U.S.-based pharmaceutical company, Puma Biotechnology, Inc. (NASDAQ:PBYI) is focused on developing and commercializing innovative cancer treatments. Its lead product, Nerlynx, is used for HER2-positive breast cancer patients to prevent recurrence. The company distinguishes itself from its competitors through targeted oncology therapies.

Puma Biotechnology, Inc. (NASDAQ:PBYI) has seen a 36.40% decline in value over the past 52 weeks owing to various reasons. Significant among them is Nerlynx’s declining sales. The company was also facing challenges in expanding the dose range for alisertib without needing further FDA consultations. It all reflected negatively on the company’s values.

However, recent trading activity indicates some positivity, with the stock having climbed 16.08% in the last month. This was after a 9% increase in NERLYNX ex-factory bottle sales during Puma Biotechnology, Inc. (NASDAQ:PBYI)’s fourth quarter. Additionally, the company conducted clinical trials, including a Phase I trial with Enhertu and two Phase II trials for alisertib – a novel aurora A kinase inhibitor under investigation for the treatment of various forms of cancer, with data expected in 2025.

With 18 hedge fund portfolios from the Insider Monkey database currently holding positions, Puma Biotechnology, Inc. (NASDAQ:PBYI) is gaining attention as a possible near-term investment opportunity among short-term stocks.